Palatin Technologies Stock Moves Higher After Outlining Plans For Dry Eye Disease Treatment

  • Palatin Technologies Inc PTN has completed an End-of-Phase 2 (EOP2) meeting with the FDA for PL9643 for the treatment of dry eye disease (DED).
  • Palatin remains on track to initiate the Phase 3 program in DED patients during Q4 of 2021, with data readout expected in 2H of 2022. 
  • If the program progresses as planned, a marketing application submission is targeted for 2H of 2023.
  • PL9643 is a novel melanocortin agonist, delivered to the eye topically via eyedrops. 
  • Palatin previously announced positive results in its Phase 2, demonstrating statistically significant improvement in multiple signs and symptoms. No safety signals were identified, and PL9643 had excellent ocular tolerability.
  • Price Action: PTN shares are up 9.88% at $0.60 during the premarket session on the last check Tuesday.

Posted In: Briefsdry eye diseasePhase 3 TrialBiotechNewsPenny StocksHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.